Baudax Bio, Inc. (NASDAQ: BXRX) announced the pricing of its public offering of 3,478,262 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock purchase warrants, at a public offering price of $1.15 per share (or pre-funded warrant).
Each share comes with one Series A-5 warrant to purchase one share of common stock at an exercise price of $1.15 per share and one Series A-6 warrant to purchase one share of common stock at an exercise price of $1.15 per share.
The Series A-5 warrants are exercisable immediately and will expire five years from the date of issuance, while the Series A-6 warrants are exercisable immediately and will expire eighteen months from the date of issuance. The closing of the offering is expected to occur on or about May 1, 2023, pending the satisfaction of customary closing conditions.
H.C. Wainwright & Co. has been appointed as the sole placement agent for the offering, making them the exclusive go-to for all your investment needs. With their expertise and knowledge, you can be sure to get the best possible deal.
The Company is thrilled to announce the launch of its public offering, which is expected to generate gross proceeds of approximately $4 million. These funds will be used to further its pipeline development activities, as well as for general corporate purposes. This offering is a tremendous opportunity for the Company to further its goals and objectives, and is a testament to its ongoing commitment to success.
The SEC has given the greenlight to the offering of the aforementioned securities, which was declared effective on April 26, 2023. Through this prospectus, included in the effective registration statement (File No. 333-271161), investors can get an overview of the investment opportunity. A preliminary prospectus has also been filed with the SEC for further review.
This is an exciting opportunity to invest in the securities described herein. Don’t miss out on this chance to purchase these securities in any state or jurisdiction, as long as they comply with the securities laws of that state or jurisdiction. Act now and take advantage of this offer!
About Baudax Bio
Baudax Bio is leading the way in innovative pharmaceuticals for hospital and related settings. With two unique neuromuscular blocking (NMBs) agents undergoing clinical trials, and a proprietary chemical reversal agent in development, the Company is paving the way for new treatments and therapies in the medical world.
Currently, the NMBs are undergoing a Phase II trial and a dose escalation Phase I trial, while the chemical reversal agent is undergoing nonclinical and manufacturing studies with an anticipated IND filing in the summer of 2023.